Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A phase 1 dose-escalation study of Navitoclax, Venetoclax, and Decitabine.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

The Clinicopathologic and Genomic Features of Mature Versus Blastic Plasmacytoid Dendritic Cell Neoplasms Arising From Chronic Myeloid Neoplasms.

The American journal of surgical pathology·2026

Same author

Live-cell Pick-Seq (LiP-Seq): Interrogating ultra-rare mantle cell lymphoma persistent cells after CART19 therapy.

Blood advances·2026

Same author

Protein <i>S</i>-acylation dynamics provide metabolic plasticity to acute myeloid leukemia cells.

bioRxiv : the preprint server for biology·2026

Same author

Synergistic targeting of eIF4A-mediated translation initiation and apoptosis in acute myeloid leukemia.

Blood neoplasia·2026

Same author

Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same journal

Impact of Treatment Sequencing With CAR T-cell Therapies and Bispecific Antibodies on Long-term Survival in 4L+ RRMM in the United States: A Simulation Model.

Clinical lymphoma, myeloma & leukemia·2026

Same journal

A Phase I Study of Copanlisib and Venetoclax in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Clinical lymphoma, myeloma & leukemia·2026

Same journal

Autoimmune Features in Myelodysplastic Syndromes: Clinical and Molecular Heterogeneity With Integrated IPSS-M Analysis.

Clinical lymphoma, myeloma & leukemia·2026

Same journal

SOHO State of the Art Updates and Next Questions | Progress in Clonal Hematopoiesis of Indeterminate Potential/Clonal Cytopenia of Uncertain Significance.

Clinical lymphoma, myeloma & leukemia·2026

Same journal

Ixazomib, Cyclophosphamide, and Dexamethasone (ICd), With or Without Daratumumab in Relapsed Multiple Myeloma.

Clinical lymphoma, myeloma & leukemia·2026

Same journal

Risk of Thromboembolic Events in Patients With Polycythemia Vera: A Real-World Observational Study.

Clinical lymphoma, myeloma & leukemia·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Dec 10, 2025

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Targeting CD123 in AML.

Andrew A Lane¹

¹Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.

Clinical Lymphoma, Myeloma & Leukemia

|September 1, 2020

Summary

This summary is machine-generated.

CD123 is a promising cell surface target for leukemia therapy, showing potential for targeted drug development. While not perfect, its characteristics make it an attractive candidate for new treatments in hematologic malignancies like AML.

Keywords:

AML BPDCN azacitidine diphthamide tagraxofusp

More Related Videos

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia

Published on: February 21, 2021

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Related Experiment Videos

Last Updated: Dec 10, 2025

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia

Published on: February 21, 2021

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Area of Science:

Hematology
Oncology
Immunology

Background:

Identifying ideal cell surface targets for leukemia therapy is crucial for treatment efficacy.
Ideal targets should be tumor-specific, essential for tumor survival, and efficiently internalized and recycled.

Purpose of the Study:

To evaluate CD123 as a potential cell surface target for leukemia therapy.
To discuss the development and application of CD123-targeting agents.

Main Methods:

Review of existing literature on cell surface targets in leukemia.
Analysis of CD123 expression and function in hematologic malignancies.
Examination of the clinical development of CD123-targeting agents like tagraxofusp-erzs (SL-401).

Main Results:

No single target perfectly meets all ideal criteria for leukemia therapy.
CD123 exhibits favorable characteristics, making it an attractive candidate despite not being ideal.
Tagraxofusp-erzs (SL-401), a CD123-targeting agent, is approved for BPDCN and under investigation for AML.

Conclusions:

CD123 represents a significant advancement in targeted therapy for hematologic malignancies.
Ongoing development of CD123-targeted drugs holds promise for treating leukemia and related disorders.